Related Experiment Video

Updated: Feb 8, 2026

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.8K

Simultaneous quantification of hepatic MRI-PDFF and R2* in a rabbit model with nonalcoholic fatty liver disease

Xiaomin Wang1,2, Xiaojing Zhang1, Lin Ma3

  • 1Department of Radiology, Chinese PLA General Hospital, Beijing, 100853, China.

Science China. Life Sciences
|June 24, 2018
PubMed

Insights

Magnetic resonance imaging (MRI) accurately quantifies liver fat in nonalcoholic fatty liver disease (NAFLD) using proton density fat fraction (PDFF). R2* measurements did not correlate with fat or iron levels in this NAFLD rabbit model.

Area of Science:

  • Hepatology
  • Medical Imaging
  • Biomedical Engineering

Background:

  • Nonalcoholic fatty liver disease (NAFLD) diagnosis and monitoring require accurate quantification of hepatic fat and iron.
  • Magnetic resonance imaging (MRI) offers a non-invasive method for assessing liver steatosis and iron overload.

Purpose of the Study:

  • To evaluate the quantification efficiency of hepatic proton density fat fraction (PDFF) by MRI in a rabbit model of NAFLD.
  • To investigate the correlation of R2* measurements with hepatic fat levels in NAFLD.

Main Methods:

  • A NAFLD rabbit model was established using a high-fat and cholesterol diet.
  • MRI examinations were performed using a 3.0T MR system with a multi-echo 3D gradient recalled echo (GRE) sequence.
  • MRI-PDFF and R2* values were compared with liver histological findings.

Main Results:

  • MRI-PDFF demonstrated significant differences across varying grades of steatosis (normal, mild, moderate, severe).
  • A strong positive correlation was observed between MRI-PDFF and histological steatosis (r=0.78, P=0.000).
  • R2* measurements did not show significant differences between steatosis grades and did not correlate with fat or iron levels.

Conclusions:

  • MRI-PDFF is an accurate method for quantifying liver fat in NAFLD.
  • Simultaneous measurement of MRI-PDFF and R2* shows promise for steatosis and iron quantification, though further investigation into R2* is needed.
Keywords:
R2*magnetic resonance imagingnonalcoholic fatty liver diseaseproton density fat fractionquantification

More Related Videos

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish09:27

Analysis of Liver Microenvironment During Early Progression of Non-Alcoholic Fatty Liver Disease-Associated Hepatocellular Carcinoma in Zebrafish

Published on: April 1, 2021

4.0K
Development and Angiographic Use of the Rabbit VX2 Model for Liver Cancer06:03

Development and Angiographic Use of the Rabbit VX2 Model for Liver Cancer

Published on: January 7, 2019

12.1K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
207
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.0K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
248
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
234
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.1K